



ASX ANNOUNCEMENT

CELLMID TO PRESENT AT PROACTIVE INVESTORS EVENTS

SYDNEY: Tuesday, 3 October 2017, Cellmid Limited (ASX: CDY) will be presenting at two events organised by Proactive Investors as follows:

Sydney

Tuesday, 3 October 2017
12-noon to 2pm
Radisson Blu Hotel, Marble Room

Melbourne

Wednesday, 4 October 2017
12-noon to 2pm
CQ Melbourne, Events Room 1, 113 Queen Street

Cellmid's presentation will primarily focus on updating on the Company's recently released results and will be based on the presentation released to the market on 27 September 2017.

End

Contact

Maria Halasz, CEO and Managing Director
T +612 9221 6830

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lynamid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. Intellectual property pertaining to midkine is being exploited through wholly owned subsidiaries Lynamid and Kinera. Advangen, Cellmid's consumer health business, sells its FGF5 inhibitor hair growth products in Australia, Japan and the USA and currently expanding distribution in other territories. For further information, please see www.cellmid.com.au, www.evolisprofessional.com.au and www.evolisproducts.com.au.